A comparison of the efficacy of naproxen sodium and a paracetamol/dextropropoxyphene combination in the treatment of soft-tissue disorders.

Ninety-eight patients were admitted to a single-blind parallel study comparing the efficacy of naproxen sodium with a paracetamol/dextropropoxyphene combination in the treatment of soft-tissue disorders. The two study groups were well matched in all respects. After seven days of treatment patients in the naproxen sodium group had less residual symptoms and more of them were considered cured. These patients also had a significantly lower mean-pain-score, tended to have less daily symptoms and recorded a significantly greater initial improvement in their condition. Fewer side-effects were recorded by the naproxen sodium-treated patients. One patient from each group withdrew from the study because of side-effects. It was concluded that in the treatment of non-articular soft-tissue disorders the use of a rapidly-acting withdrew anti-inflammatory drug, naproxen sodium, gave a better clinical response than did treatment with a simple analgesic combination.     

Naproxen sodium and paracetamol/dextropropoxyphene in sports injuries - a multicentre comparative study.

This paper follows up a previous paper reported in this journal. This study was a single-blind parallel comparison of naproxen sodium ("Synflex") and a paracetamol/dextropropoxyphene combination ("Distalgesic"). It was carried out in 184 patients suffering from soft-tissue disorders recruited from four centres. More patients were considered cured and the pain score was significantly lower after seven days' treatment in the naproxen sodium ("NS") group. For those patients who received 14 days' treatment the total symptom score was significantly lower in the naproxen sodium group at the end of treatment. Two patients in the NS treatment group withdrew from the study due to lack of efficacy. Fewer side-effects were reported in the NS group. Of the eight patients stopping treatment due to side-effects, two were in the naproxen sodium group and six in the paracetamol/dextropropoxyphene ("control") group. The results suggest that a better clinical response to treatment and fewer side-effects may be obtained with naproxen sodium than with paracetamol/dextropropoxyphene in the treatment of soft-tissue injuries.     

Efficacy of celecoxib, a COX-2-specific inhibitor, and naproxen in the management of acute ankle sprain: results of a double-blind, randomized controlled trial.

OBJECTIVE: To assess the efficacy and safety of celecoxib and naproxen in the treatment of acute ankle sprain. DESIGN: Double-blind, parallel-group, randomized trial. SETTING: Multicenter outpatient. PATIENTS: Adult patients (n = 397) with acute first-degree or second-degree ankle sprain. INTERVENTIONS: Patients randomized to celecoxib 200 mg b.i.d. (n = 198) or naproxen 500 mg b.i.d. (n = 198) for 7 days. MAIN OUTCOME MEASURES: Primary measures of efficacy were Patient's Assessment of Ankle Pain Visual Analogue Scale (VAS) and Patient's Global Assessment of Ankle Injury. Secondary efficacy measures included Physician's Global Assessment of Ankle Injury, Patient's Return to Normal Function/Activity, and Patients' and Physicians' Satisfaction Assessments. Adverse events (AEs) were reported by investigators during the study. RESULTS: For the primary endpoints at day 4, the mean pain VAS scores were 31.9 mm +/- 1.96 for celecoxib and 29.0 mm +/- 1.91 for naproxen, and the responder rate for Patient's Global Assessment of Ankle Injury was 71% in the celecoxib group and 72% in the naproxen group, differences that were not statistically significant. In addition, noninferiority analysis demonstrated treatment differences that were within prespecified minimal clinical important differences. Gastrointestinal AEs were the most common AE, accounting for 14% in the celecoxib group and 21% in the naproxen group. The incidence of dyspepsia was 3% for celecoxib compared with 12% for naproxen (P = 0.032). CONCLUSIONS: Celecoxib is as effective as naproxen in treating acute first-degree or second-degree ankle sprains but causes significantly less dyspepsia.     

正清风痛宁对类风湿性关节炎的治疗价值

目的观察正清风痛宁联合西药治疗类风湿性关节炎的疗效。方法将72例类风湿性关节炎患者,随机分为治疗组和对照组。对照组予萘普生、泼尼松、甲氨蝶呤、柳氮磺吡啶,以及对症治疗;治疗组在对照组治疗基础上加用正清风痛宁缓释片治疗,疗程半年。结果除治疗组2例、对照组3例失访或未坚持治疗外,治疗半年后,两组其余病人的关节疼痛、肿胀、压痛,关节活动度、晨僵时间,均有明显的改善与好转,但治疗组总有效率97.2%,疗效明显优于对照组的87·5%,且副作用轻微。结论正清风痛宁联合西药治疗类风湿性关节炎,效果显著,安全性较好。     

加替沙星、呋喃唑酮、埃索美拉唑根除幽门螺杆菌临床疗效观察

 目的 探讨加替沙星、呋喃唑酮、埃索美拉唑联合应用1周后,第8天开始单独服用埃索美拉唑40 mg,1/d,共3周根除幽门螺杆菌(Hp)的疗效.方法 选择符合条件的80例十二指肠溃疡患者随机分成两组,第1周治疗组口服加替沙星200 mg,2/d,呋喃唑酮100 mg,2/d,埃索美拉唑40 mg,1/d;对照组口服克拉霉素500 mg,2/d,呋喃唑酮100 mg,2/d,埃索美拉唑40 mg,1/d.第8天开始两组均单独服用埃索美拉唑40 mg,1/d,共3周.治疗完成4周后复查胃镜及做Hp检查.结果 治疗组、对照组Hp根除率分别为95%、87.5%,溃疡愈合率97.5%、95%,两组相比,差异均无统计学意义(P＞0.05).未发生严重不良反应.结论 加替沙星、呋喃唑酮、埃索美拉唑三联疗法能有效、安全根除幽门螺杆菌,治疗十二指肠溃疡疗效佳.     

奥扎格雷钠联合阿司匹林治疗急性脑梗死的临床研究

目的 观察奥扎格雷钠联合阿司匹林治疗急性脑梗死的临床疗效和安全性.方法发病后6-48 h入院的非心源性急性脑梗死患者随机分为两组,A组（n=65）给予奥扎格雷钠（80 mg/次,2次/d）＋阿司匹林肠溶片（100 mg/次,1次/d）,B组（n=65）给予阿司匹林肠溶片（100 mg/次,1次/d）,疗程均为14 d.治疗前后均进行神经功能缺损量表（NIHSS）评分和肌力测评,并观察治疗期间发生的不良反应及出血性并发症.结果两组治疗后14 d,神经功能缺损程度较基线水平均明显改善（P＜0.01）,而A组的神经功能缺损症状及肌力恢复均显著优于B组（P＜0.01）;A组发生1例出血性转化,4例血尿;B组发生1例血尿,两组均无消化道出血,两组在出血并发症方面无显著性差异（P＞0.05）.结论 对于发病后6~48 h就医的急性脑梗死,奥扎格雷钠联合阿司匹林是一种安全、有效的治疗方法.     

通心络胶囊治疗类风湿关节炎的临床观察

目的观察通心络胶囊联合西药治疗类风湿性关节炎的疗效。方法88例类风湿性关节炎患者,随机分为治疗组和对照组。对照组予萘普生、泼尼松、甲氨蝶呤、硫酸羟氯喹,以及对症治疗;治疗组在对照组治疗基础上加用通心络胶囊每次4粒,2次/d。疗程半年。结果除治疗组1例未坚持治疗外,治疗半年后,两组其余病人的关节疼痛、肿胀、压痛、关节活动度、晨僵时间,均有明显的改善。治疗组总有效率95.4%,疗效明显优于对照组(88.6%),且副作用轻微。结论通心络胶囊联合西药治疗类风湿性关节炎,效果显著,安全性较好。     

孟鲁司特钠治疗成人感染后咳嗽临床观察

目的观察成人感染后咳嗽应用孟鲁司特钠的临床疗效,为临床治疗成人感染后咳嗽提供依据。方法选取感染后咳嗽的成年患者112例,随机分为基础治疗组与孟鲁司特钠组,每组各56例。基础治疗组:雾化吸入布地奈德混悬液1 mg,每天2次;口服右美沙芬片15 mg,每天3次。孟鲁司特钠组:基础治疗组上联合口服孟鲁司特钠片10 mg,每天1次。疗程均为1周。比较两组患者治疗前后咳嗽积分、临床有效率及不良反应发生概率。结果治疗前,两组患者咳嗽积分比较,差异无统计学意义(P>0.05);治疗后,两组患者咳嗽积分均较治疗前明显下降,孟鲁司特钠组患者咳嗽积分明显低于基础治疗组,差异均有统计学意义(P<0.05)。孟鲁司特钠组临床有效率(92.9%,52/56)明显高于基础治疗组(71.4%,40/56),差异有统计学意义(P<0.05)。两组患者不良反应发生概率比较,差异无统计学意义(P>0.05)。结论在布地奈德与右美沙芬的基础上联合应用孟鲁司特钠,可提高成人感染后咳嗽的临床疗效,且安全性高,值得临床推广。     

The COX-2 specific inhibitor Valdecoxib versus tramadol in acute ankle sprain: a multicenter randomized, controlled trial

BACKGROUND: The cyclooxygenase-2 specific inhibitor valdecoxib has not been approved in the United States for treatment of acute pain. HYPOTHESIS: Valdecoxib 20 mg twice daily or once daily (both with a 40-mg loading dose) is not clinically inferior to tramadol for treating the signs and symptoms of acute ankle pain. STUDY DESIGN: Randomized, controlled clinical trial; Level of evidence, 1. METHODS: Patients (N = 829) with acute first- or second-degree ankle sprain received 7 days' treatment with valdecoxib 20 mg either twice daily or once daily (both with 40-mg loading dose), tramadol 50 mg 4 times daily, or placebo. The primary end point was Patient's Assessment of Ankle Pain visual analog scale on day 4; a test of noninferiority compared valdecoxib with tramadol. RESULTS: On day 4, both valdecoxib doses were significantly better versus placebo and were comparable with tramadol in relieving ankle pain. On day 7, valdecoxib, but not tramadol, significantly reduced pain versus placebo. On days 4 and 7, more patients resumed normal walking with valdecoxib (45%-47% and 73%-79%, respectively) than with placebo (35% and 64%, respectively) or tramadol (38% and 67%, respectively). In contrast to valdecoxib, the number of withdrawals due to adverse events was significantly higher in the tramadol group (12.2% vs 3.4%; P = .0005). CONCLUSIONS: Valdecoxib was comparable with tramadol and was significantly better than placebo in treating acute ankle sprain, and it enabled more patients to resume normal walking on days 4 and 7. Both valdecoxib and tramadol were well tolerated.     

多库酯钠治疗慢性功能性便秘的疗效分析

目的观察多库酯钠治疗慢性功能性便秘的疗效和安全性。方法按入组标准将60例功能性便秘患者随机分为2组。治疗组口服多库酯钠（100 mg,每天3次）治疗,对照组口服乳果糖（30 ml,每天1次）治疗,疗程2周。结果在用药1周后、用药2周后及治疗结束后1周,治疗组的大便次数及大便性状评分较对照组有统计学意义（P〈0.05）。两组临床疗效比较无统计学意义,但治疗组在用药1周后、用药2周后显效率显著高于对照组（P〈0.05）。两组不良反应的发生率均较低。结论多库酯钠治疗慢性功能性便秘临床效果明显,安全可靠。     

Study of response to naproxen in patients with hepatocellular carcinoma who developed fever following transcatheter arterial embolization

Good antipyretic response was obtained when naproxen was given at 600 mg/day for about one week to patients who developed fever after transcatheter arterial embolization (TAE). Fever recurred in several patients, but subsided again when naproxen was given at 300 mg/day. No patients developed gastric mucosal lesions of clinical concern that seemed to be related to naproxen.     

The effect of analgesic agents on the healing rat medial collateral ligament

BACKGROUND: Studies have suggested that some nonselective nonsteroidal anti-inflammatory drugs, including piroxicam, may improve ligament healing, whereas other nonsteroidal anti-inflammatory drugs, including ibuprofen and the cyclooxygenase-2 inhibitor celecoxib, may have no effect on the mechanical properties or may even deter the healing process. These results might reflect variations in cyclooxygenase enzyme selectivity by different drugs or, alternatively, may be related to their analgesic properties because it is generally accepted that early activity improves ligament healing. HYPOTHESIS: Nonselective nonsteroidal anti-inflammatory drugs improve ligament healing, whereas other analgesics provide lesser degrees of improvement, and cyclooxygenase-2 inhibitors are detrimental. STUDY DESIGN: Controlled laboratory study. METHODS: One hundred fifty-five Sprague-Dawley rats were divided into 7 treatment groups (piroxicam, naproxen, rofecoxib, butorphanol, 2 doses of acetaminophen, and control). The right medial collateral ligament of each rat was transected, and the drugs were administered postoperatively on days 1 to 6. On day 14, the rats were sacrificed, and mechanical testing was performed on the medial collateral ligament. RESULTS: The piroxicam group demonstrated significantly greater load to failure (27%) compared with the control. No significant differences were observed between other groups. CONCLUSIONS: Piroxicam improves ligament healing, but this effect cannot be attributed to all nonselective nonsteroidal anti-inflammatory drugs. Opiate analgesics, acetaminophen, and cyclooxygenase-2 inhibitors do not appear to categorically affect ligament healing. CLINICAL RELEVANCE: In the treatment of ligament injury, piroxicam may be a drug of choice.     

Variable schedules of ibuprofen for ankle sprains.

In a study of 144 patients, with Grade 1 and 2 inversion injuries to the ankle sustained in sport, treatment with a non-steroidal anti-inflammatory was considerably superior to placebo with respect to joint tenderness, level of training and injury severity. No difference in efficacy could be determined between ibuprofen 2400 mg given in two or four equally divided daily doses. Ten patients withdrew from the study because of side effects, five from ibuprofen twice daily, three from ibuprofen four times daily and two from the placebo group. This study confirms the efficacy, flexibility and tolerability of high dose ibuprofen.     

The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.

(186)Re-1,1-hydroxyethylidene diphosphonate (etidronate) can be used for the palliative treatment of metastatic bone pain. A randomized, placebo-controlled study using (186)Re-etidronate was conducted on end-stage prostate cancer patients with metastatic bone pain. METHODS: Pain relief was assessed using an electronic diary containing questions reflecting the multidimensional character of chronic pain. The diary was marked twice daily for a maximum of 14 wk (2 wk before and 12 wk after the injection). Pain response was determined using a specific decision rule in which pain intensity, medication index, and daily activities were the core determinants. A positive response day was defined as a day on which pain intensity was reduced > or = 25% compared with baseline values, while medication index and daily activities were at least constant, or on which pain intensity was reduced < 25% and medication index or daily activities improved > or = 25%, without worsening of the remaining factor. The total response (%) was defined as the number of positive response days divided by the number of days of follow-up. RESULTS: Of the 111 included patients, 79 were evaluable (43 (186)Re-etidronate, 36 placebo). Thirty-two patients were excluded from the analysis because of incomplete datasets. The total response of the patients treated with (186)Re-etidronate varied from 0% to 96% (mean, 27%, or 23/84 d). In the placebo group, the total response varied from 0% to 80% (mean, 13%, or 11/84 d; Mann-Whitney U test, P < 0.05). The number of patients who requested radiotherapy was higher in the placebo group (67%) than in the (186)Re-etidronate group (44%) (relative risk, 1.51; Fisher's exact test, P = 0.069). CONCLUSION: This randomized controlled trial confirmed that, compared with placebo, (186)Re-etidronate resulted in a significantly longer pain response in the treatment of bone pain from metastasized prostate cancer.     

唑来膦酸钠治疗骨质疏松症的效果评价（附60例）

目的：探讨唑来膦酸钠对骨质疏松症的治疗效果。方法：120例骨质疏松症患者随机分为观察组及对照组各60例,观察组唑来膦酸注射5mg1次;对照组钙尔奇（含钙500mg和VitD3）1片,1次/d。在基线调查的基础上,12个月左右进行随访。结果：治疗后观察组骨痛症状评分明显下降、骨痛缓解与对照组比较差异有显著性（P〈0.05）,观察组骨密度增加明显（P〈0.05）,观察组主要副作用为流感样症状及消化道反应,能耐受。结论：唑来膦酸钠治疗骨质疏松症疗效显著、不良反应少。     

高乌甲素用于腹腔镜胆囊切除术后镇痛的临床观察

目的　观察高乌甲素在腹腔镜胆囊切除 (LC)术后 2 4h的镇痛效果。方法　择期LC手术患者 60例随机分为三组 ,Ⅰ组 (n =2 0 )高乌甲素 4mg肌注 ,Ⅱ组 (n =2 0 )高乌甲素 8mg肌注 ,Ⅲ (n =2 0 )对照组。Ⅰ ,Ⅱ组均于手术结束前 2 0min给药 ,Ⅲ组不做镇痛处理 ,采用视觉模拟评分 (VAS)法分别对三组术后 2 ,6,12 ,2 4h进行疼痛评分并记录下床活动时间 ,病人满意率及皮肤瘙痒、恶心呕吐等副反应。结果　术后2 4h内Ⅰ ,Ⅱ组VAS分较对照组有显著差异 (P <0 .0 5 ) ,且Ⅰ ,Ⅱ组比对照组下床活动早、满意率高也不增加瘙痒、恶心呕吐等副反应。结论　应用高乌甲素 4～ 8mg对LC术后镇痛有良好效果 ,不增加副作用。     

埃索美拉唑干预胃食管反流患者夜间酸突破的临床研究

 目的探讨埃索美拉唑干预胃食管反流病患者(GERD)的夜间酸突破(NAB)现象及其与幽门螺杆菌(Hp)感染之间的关系.方法GERD患者随机分为5组,每组10例,分别接受:A组:口服埃索美拉唑40mg,1/d;B组:口服埃索美拉唑40mg,2/d;C组:口服埃索美拉唑40mg,早1次,口服高舒达20mg,晚1次;D组:口服埃索美拉唑40mg,2/d,睡前口服高舒达20mg,1次;E组:口服高舒达20mg,2/d.均用药7 d并于第7天早上8时起连续24h监测其胃内pH值.结果5组患者的平均胃内pH值、平均中位pH值、夜间平均胃内pH值和夜间平均中位pH值均有不同程度升高,B、C、D组升高明显,显著高于A、E组(P＜0.05);A、E组夜间pH＜4.0的时间占夜间监测时间的百分比显著高于B、C、D组(P＜0.05);埃索美拉唑2次用药组仅有1例NAB发生(2.0%),显著低于1次用药组(P＜0.05).结论GERD患者NAB的发生与埃索美拉唑剂量、用药方法、是否加用高舒达及Hp感染相关.     

前列腺素E_1在冠状动脉搭桥手术中应用的研究

目的观察前列腺素E1(PGE1)对冠状动脉搭桥术的心功能和氧合的改善。方法将60例拟行冠状动脉搭桥术的患者随机分为两组,治疗组(30例)在气管插管后即开始予0.9氯化钠+PGE1注射液10μg静脉滴注,1次/d,连续3 d,对照组(30例)予0.9氯化钠静脉滴注,1次/d,连续3 d。气管插管同时及手术结束后当时、术后次日、术后第3天,采集肺动脉压力(平均压mPAP),采集患者桡动脉血,检测氧分压(PaO2)、二氧化碳分压(PaCO2)。记录患者带呼吸机辅助呼吸时间,术后第5天,给予患者复查左室射血分数。结果治疗组患者在氧饱和度、PaO2、呼吸机辅助呼吸时间、肺动脉压力、术后心功能方面,均较对照组有了明显的改善。结论 PGE1对冠状动脉搭桥术患者的心功能和氧合方面都能起到改善的作用。     

Pre- and postoperative intra-articular analgesia for arthroscopic surgery of the knee and arthroscopy-assisted anterior cruciate ligament reconstruction A double-blind randomized, prospective study

We tested the effectiveness of different intra-articular analgesics and of pre-emptive intra-articular analgesia for arthroscopy-assisted anterior cruciate ligament reconstruction (ACLR) and for operative knee arthroscopy. Eighty-two patients underwent operative knee arthroscopy under selective subarachnoid anaesthesia (group A), and 60 patients underwent arthroscopy-assisted ACLR under general anaesthesia (group B). Patients were randomly assigned to intra-articular analgesic treatment as follows. Group A: 1, morphine 2 mg; 2, preoperative morphine 2 mg; 3, morphine 5 mg; 4, preoperative morphine 5 mg; 5, bupivacaine 0.25% 20 ml; 6, bupivacaine 0.25% 20 ml + morphine 2 mg; 7, saline solution 20 ml. Group B: 1, morphine 2 mg; 2, morphine 5 mg; 3, preoperative morphine 5 mg; 4, bupivacaine 0.25% 20 ml; 5, bupivacaine 0.25% 20 ml + morphine 2 mg; 6, saline solution 20 ml. All opioids were diluted in 20 ml of saline solution. After postoperative administration the tourniquet was left in place for 10 min. After preoperative administration the intra-articular surgical procedure was delayed for about 5–10 min. In the postoperative period we recorded: total consumption of ketoprofen given i.v. on demand as rescue analgesic treatment; pain scores before surgery and at 1st, 3rd, 6th, 12th and 24th h; occurrence of local anaesthetic or opioid side-effects. Group A (operative knee arthroscopy): all morphine groups (A1, A2, A3, A4) and the bupivacaine group (A5) did not require ketoprofen postoperatively (P < 0.01 vs both groups A6 and A7). Pain scores did not differ significantly among groups. The percentage of patients reporting higher pain scores than before surgery was larger in control group A7 and in bupivacaine groups A5, A6 (83%, 40%, 60%, respectively) and lower in morphine groups A1, A2, A3, A4 (25%, 16%, 27%, 23%, respectively). Group B (ACLR): total consumption of ketoprofen was lowest in groups B2 and B3 (P < 0.001 vs all other treatments and vs control group). The percentage of patients who did not require any rescue analgesic was 60% in group B3, 50% in group B2, 32% in group B5 and 0% in all other groups. No-side effects occurred in any patient. Intra-articular analgesia is safe and effective for arthroscopic knee surgery. Morphine provides a better pain control both in operative knee arthroscopy patients and in ACLR. A 2 mg dose is adequate for operative knee arthroscopy but not for ACLR, where higher dosages are required (5 mg). Pre-emptive intra-articular morphine provides better analgesia than postoperative administration. Received: 25 May 1996 Accepted: 28 April 1997     

厄贝沙坦片和厄贝沙坦氢氯噻嗪片治疗轻中度高血压病疗效观察

目的比较厄贝沙坦片和厄贝沙坦氢氯噻嗪片对轻中度高血压患者的降压疗效。方法将80例轻中度高血压患者随机分为厄贝沙坦片治疗组（n=40）和厄贝沙坦氢氯噻嗪片治疗组（n=40）。结果治疗第8周时厄贝沙坦片治疗组和厄贝沙坦氢氯噻嗪片治疗组有效率分别为85%、90%（P〉0.05）。两组收缩压及舒张压均显著降低,两组间降压程度无显著性差异。结论两种药物均能有效降低血压。